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Objectives: Despite the American Heart Association’s interest in research on 
the determinants of health-related quality of life (HRQoL) among Acute Coronary 
Syndrome (ACS) survivors, little is known about trajectories of HRQoL post-ACS. 
We sought to identify such longitudinal patterns, and their predictors, over the 
6 months post-ACS discharge. MethOds: We used data from the Transitions, 
Risks, and Actions in Coronary Events – Center for Cardiovascular Outcomes and 
Education (TRACE-CORE) prospective cohort of patients hospitalized with ACS. 
HRQoL was measured using the Seattle Angina Questionnaire (SAQ) at the index 
hospitalization and at 1-, 3 -, and 6-months post-discharge. The quality of life 
subscore of the SAQ ranges 1-100 with higher scores indicating better HRQoL. We 
used trajectory analysis to identify subgroups of patients with distinctive 6-month 
post-discharge HRQoL patterns, and predictors of different trajectories. Results: 
Participants (N= 920) had mean age 63 (SD 11) years, 34% were female, and 
83% non-Hispanic white. We identified 3 HRQoL trajectories (FAIR, GOOD, and 
EXCELLENT HRQoL) consisting of 12.1%, 53.8% and 34.1% of participants, respec-
tively: FAIR (baseline average HRQoL = 38.8, and remaining low over the 6-month 
follow-up); GOOD (baseline average = 62.6 and increasing modestly over time); 
and, EXCELLENT (baseline average = 87.0 and remaining high). With FAIR HRQoL 
as the referent, we found that older age predicted better HRQoL (OR per year for 
GOOD = 1.09 and for EXCELLENT = 1.18) as did non-Hsipanic white race/ethnic-
ity (OR for GOOD = 3.01; for EXCELLENT = 4.21) and male sex (OR for GOOD= 1.17 
p= 0.56, for EXCELLENT = 2.57). [All p < 0.05, except as noted.] cOnclusiOns: On 
average, HRQoL was relatively stable over time, and no trajectories with decreasing 
HRQoL were found. Early HRQoL scores could direct resources to improve HRQoL 
over the first 6 months post-ACS.
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Objectives: Since 2005, the American Diabetes Association’s (ADA’s) Standards 
of Medical Care in Diabetes have recommended that elderly diabetic patients 
with overt cardiovascular disease (CVD) or CVD risk factors should take statins 
to manage lipid levels. The objectives of this study were to 1) provide national 
estimates of statin utilization, and 2) identify predictors of statin use in elderly 
Medicare beneficiaries with diabetes to whom the ADA’s Standards of Medical Care 
apply. MethOds: This study was a pooled cross-sectional study of the Medicare 
Current Beneficiaries Survey (MCBS) from 2006 to 2010. Sampling weights were 
applied to generate national estimates. Weighted logistic regression was performed 
to identify predicators of statin use. Results: Among 8,539 person-years of elderly 
diabetic patients, 8,115 (94.69%, weighted percentage) were eligible for statin therapy 
according to the ADA’s Standards of Medical Care. In 2006, 2007, 2008, 2009, and 2010, 
55.27%, 53.30%, 53.23%, 57.86%, and 60.70% of eligible diabetics used statins, respec-
tively. Predictors of non-use of statin included: being non-Hispanic black (odds ratio 
[OR]: 0.69; 95% confidence interval [CI]: 0.56-0.84), living in non-metropolitan areas 
(OR: 0.78; 95% CI: 0.69-0.88), being underweight, with a body mass index of 18.5 or 
under, (OR: 0.27; 95% CI: 0.13-0.54), having one or more comorbidities in addition to 
CVD (OR: 0.81; 95% CI: 0.68-0.95), and having CVD risk factors (OR: 0.59; 95% CI: 0.51-
0.67). cOnclusiOns: A 10% increase in statin use was observed among diabetic 
patients who satisfied ADA’s criteria for statin use between 2006 and 2010. Still, 
approximately 40% of eligible individuals with diabetes were not taking statins in 
2010. For elderly Medicare beneficiaries with diabetes, healthcare providers should 
be aware of patient factors associated with statin non-use and provide interventions 
to improve prescribing patterns and patient adherence.
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bAckgROund: Obesity is a chronic condition and its clinical and economic conse-
quences are very concerning. Obesity and its co-morbidities were associated with 
USD 2.1 billion annually costs in the Brazilian Public Health System. According to 
a National Survey there are 22 million people in Brazil with BMI > 30kg/m2. Also 
there are 13.5 million diabetic people, many of them being obese Objectives: To 
describe epidemiology, treatment patterns, resource use and associated costs of 
morbid obese patients in the list, waiting to receive surgical treatment for surgery 
in order to quantify the clinic and economic burden of not providing surgical treat-
ment to eligible patients MethOds: Non-interventional, single center, retrospec-
tive cohort with medical chart review of 300 patients who met eligibility criteria, 
having their registry data extracted and outcomes followed-up for up to 12-months 
post-bariatric-surgery Results: The mean time in the waiting list was 751.76 days. 
BMI mean at baseline was 46,53 kg/m2 (95% CI 45,67-47,39); 43,78 kg/m2 (95% CI 
42,98-44,59) at surgery and 30,91 kg/m2 (95% CI 30,29-31,55) at 12-months follow-up. 
195(65%) of patients presented hypertension at baseline, which 92,8% presented 
improvement/resolution 12-months after surgery. 70(23,3%) presented dyslipidemia, 
with resolution of 94,3% after 12-months. 55(18,33%) presented diabetes, with res-
olution of 94,3% after 12-months. 37 (12,33%) patients increased BMI during the 
wait list., these patients presented lower comorbidities resolution rates compared 
to patients who maintained or reduced their BMI in the wait list cOnclusiOns: 
Analysis demonstrated high comorbidities resolution rates after 12 months of follow 
for age, sex, blood pressure (BP) stage and history of stroke, we found that the utili-
ties in older patients were lower than those of the younger groups, and statistically 
significantly differing if compared the extremes of youngest and oldest groups 
were considered (p= 0.03). Utility in males was higher than in females (p= 0.002). 
Patients with a history of stroke exhibited lower utility than patients without such 
history, although not statistically significant (p= 0.73). Patients with more than 
3 comorbidities had lower utilities than patients without comorbidity (p= 0.01). 
Statistically in significantly relatively higher BP was associated with lower utility 
at 0.734, 0.726 or 0.712 in the groups with target BP, stage 1 and 2, respectively (p= 
0.422). cOnclusiOns: Mean utility was estimated at 0.72 in hypertensive patients 
in Vietnam. In contrast to BP staging and history of stroke, gender was found as a 
statistically significant predictor of utility. In addition, patients who experience 
more than 3 comorbidities or older than 70 had statistically significant lower utili-
ties.
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Objectives: There is limited information on drivers of utilities in patients with 
chronic heart failure (CHF). We analyzed determinants of utility in CHF and driv-
ers of change over one year in a large sample from clinical practice. MethOds: 
We included 5334 patients from the Swedish Heart Failure Registry with EQ-5D 
information available following inpatient or outpatient care during 2008 to 2010; 
3495 had 1-year follow-up data. We applied ordinary least squares (OLS) and two-
part models for utility at inclusion, OLS regression for change over one year, all 
with robust standard errors. We assessed predictive accuracy of both models using 
cross-validation. Results: Mean age was 73 years, 65% were male, 19% had a left 
ventricular ejection fraction ≥ 50%, 23% 40-49%, 27% 30-39%, and 31% < 30%. For both 
models, utility at inclusion was negatively affected by female gender, increasing 
age, increasing New York Heart Association (NYHA) class, preserved left ventricular 
ejection fraction, lung disease, diabetes, and use of nitrates, antiplatelets or diuret-
ics. Higher systolic blood pressure and haemoglobin levels and use of angiotensin 
converting enzyme inhibitors/angiotensin receptor blockers or beta-blockers were 
associated with increased utility. A significant interaction between age category 
and functional class indicated that patients in the youngest age group are more 
severely affected by worsening functional status than older patients. The OLS model 
performed slightly better than the two-part model on a population level and for 
capturing utility ranges. Change in utility over one year was influenced by age, 
gender, disease duration, and (measured at inclusion) NYHA class, blood pressure, 
ischemic heart disease, lung disease, angiotensin converting enzyme inhibitors/
angiotensin receptor blockers and antiplatelets. cOnclusiOns: Utilities in CHF 
and their change over time are influenced by diverse demographic and clinical 
factors. Our findings can be used to target clinical interventions and for economic 
evaluations of new therapies.
PCv91
validation of a syndrome-sPeCifiC instrument to assess angina 
treated by traditional CHinese mediCine (tCm-saq): tHe ability to 
deteCt CHange
Zhang H.Y., Yu L., Lv M.J., Chen Z.H., Yang G.L.
Liaoning University of Traditional Chinese Medicine, Shenyang, China
Objectives: The TCM-SAQ was a valid and reliable syndrome-specific instruction 
to assess quality of life (QoL) for angina treated by traditional Chinese medicine. 
However, its ability to detect change has not been discussed. This study was aimed 
to investigate the ability of detecting change over time of the TCM-SAQ. MethOds: 
The data is performed from an Random Clinical Trail. Patient diagnosed with angina 
pectoris were enrolled in ten Chinese medical hospitals in the northeast of China, 
from June, 2011 to May, 2012. All enrolled patients were treated by Chinese herbs 
combined with aspirin and Lipitor for 8 weeks; nitrates were used to release angina 
attack. Angina symptoms (frequency, duration, pain degree) were used to assess the 
therapeutic efficiency; lower scores represent better angina conditions. TCM-SAQ 
was tested at the enrollment and 8th weeks of the treatment, higher scores means 
better quality of life. Results: Analysis is based on 240 patients (age 60±7years; 
111 male, 52%). The disease history is 3.5±3.5 years. Seventy-nine (32.9%) patients 
have at least one comorbidity. The average angina attack times per week before 
the treatment is 6.28, and 2.36 after eight weeks’ treatment, which declined 3.97 
times; the average angina attack duration is 5.73 before, and 2.56 after, and angina 
score declined 4.1 after the treatment. TCM-SAQ shows a significant improved of 
QoL in each domain as well as the angina condition changes (P= 0.000). Of all those 
patients, 64 patient’s (26.7%) angina condition remained unchanged, and 176 (73.3%) 
improved. Therapeutic effective patients show a better QoL than invalid patients. 
TCM-SAQ can detect the differences between effective and invalid patients in 
domains(p= 0.000). cOnclusiOns: The TCM-SAQ has a good ability to detect clini-
cal change over time in individuals, and it also can detect the differences between 
known groups. In the future, we need to determine the minimal clinic differences 
of TCM-SAQ.
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